Bridgewater-based Cosette Pharmaceuticals has appointed David Bell as Chief Commercial Officer (Brands).
He joins the branded specialty pharmaceutical company’s executive leadership team as it continues to expand its commercial platform and portfolio.
In this role, Bell will oversee all branded commercial functions – including sales, marketing, market access, commercial operations, analytics, and portfolio strategy.
He will be responsible for driving performance across Cosette’s marketed portfolio of 21 brands, supporting the integration and growth of acquired assets, and ensuring strong alignment between commercial execution and the company’s broader strategic and financial objectives, according to a release.
Bell brings more than 25 years of commercial and enterprise leadership experience across oncology, rare disease, and gene therapy in specialty pharmaceutical markets.
Most recently, he served as Vice President and Business Unit Head, US Oncology, at Ferring Pharmaceuticals, where he had full U.S. P&L ownership responsibilities. Bell also previously served as Franchise General Manager at Melinta Therapeutics and spent 17 years at Merck & Co./Schering-Plough in progressive global, U.S., and regional commercial leadership roles.
Bell has a Master of Business Administration and a Bachelor of Science in Finance from Seton Hall University’s W. Paul Stillman School of Business. He also served as a board member of Enhanced HealthCare Solutions.
In late April, Cosette Pharmaceuticals, Inc., appointed Erika Tooman as senior vice president and general counsel. The move is a strategic play to fortify the company’s executive bench as it aggressively scales its platform through acquisitions and new partnerships.
